Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6


A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.

Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM; Children's Oncology Group.

Clin Cancer Res. 2006 Mar 15;12(6):1750-9.


The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.

Yamane BH, Hank JA, Albertini MR, Sondel PM.

Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000. doi: 10.1517/13543780903048911. Review.


Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.

Parsons K, Bernhardt B, Strickland B.

Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Review.


64Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-p-benzyl-NH-hu14.18K322A.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Dec 16 [updated 2013 Mar 14].


Dinutuximab for maintenance therapy in pediatric neuroblastoma.

McGinty L, Kolesar J.

Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567. doi: 10.2146/ajhp160228. Review.


Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics.

León K, García-Martínez K, Carmenate T.

Front Immunol. 2013 Dec 11;4:439. doi: 10.3389/fimmu.2013.00439. Review.

Supplemental Content

Support Center